NASDAQ : XRTX | TSXV : XRTX.V
Pioneering New Therapies for Progressive Kidney Disease
We are XORTX Therapeutics, a biotechnology company dedicated to developing innovative therapies to improve the quality of life of patients with progressive kidney disease. Our programs are designed to manage aberrant purine metabolism and reduce high uric acid and slow progression of kidney disease.
This form collects information we will use to send you updates about promotions, special offers, and news regarding BTV and XORTX Therapeutics. We will not share or sell your personal information. You can unsubscribe at any time. Please read our privacy policy for more information.
Developing First-in-class Uric Acid Lowering Agents
We have three programs, two of these programs are in clinical development and one is at an early stage of development, each is intended to treat rare and progressive kidney disease modulated by aberrant purine and uric acid metabolism.
XRx-008 for Autosomal Dominant Polycystic Kidney Disease
We are currently developing XRx-008 for the treatment for progressive autosomal dominant polycystic kidney disease (ADPKD), a genetic disorder that’s known to cause declining kidney function leading to end stage kidney disease and cardiovascular disease.
XRx-101 for Diseases Caused by Coronavirus Infections
XRx-101 is a novel proprietary formulation that focuses on decreasing uric acid. The company believes that this approach has the potential to treat acute kidney and other health consequences associated with serious viral infections such as have been described for Coronavirus/COVID-19.
XRx-225 for Type 2 Diabetic Nephropathy
We are co-developing XRx-225 for the treatment of Type 2 Diabetic Nephropathy (T2DN), one of the most common causes of chronic kidney failure and end-stage kidney disease in the U.S. and worldwide.
Powered By:
Copyright © 2022. All rights reserved.